J.P. Morgan analyst Anupam Rama has maintained their bullish stance on VERA stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Anupam Rama’s rating is based on several key factors that highlight the potential of Vera Therapeutics’ atacicept. The recent market reaction to Otsuka’s announcement regarding sibeprenlimab appears to be exaggerated, especially considering the regulatory uncertainties and lack of long-term patient exposure for Otsuka’s product. In contrast, atacicept has demonstrated a significant advantage as the only b-cell modulator with two-year at-home exposure and a proven eGFR benefit in phase 2 trials.
Furthermore, the anticipated pivotal data from the ORIGIN-3 trial in the second quarter of 2025 could be a strong positive catalyst for the stock. The expected regulatory benchmark of a 30% placebo-adjusted reduction in proteinuria supports the long-term value of atacicept. Given these factors, Rama sees potential for VERA shares to trade into the mid-$40s, reinforcing the Buy rating with an Overweight classification on the J.P. Morgan Analyst Focus List.
Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Olema Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Rama has an average return of 0.8% and a 42.94% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $70.00 price target.